Építés alatt – nem éles oldal
Belépés
BefejeződöttFázis nélkül

Controlled Arterial Protection to Ultimately Remove Embolic Material

A legfontosabb adatok

Ki végzi
EmStop Inc
Hol
Asheville és Nashville (Egyesült Államok)Mind a 2 helyszín megnézése
Azonosító
Állapot
Befejeződött
Résztvevők
15 fő vett részt
Kezdés
2023. dec. 27.
Befejezés
2024. okt. 14.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • The EmStop Embolic Protection System (EmStop System)
A regiszteradat frissítve
2025. április 29.

Ki vehet részt

Életkor
21 év – 90 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 25 feltétel megnézéseKevesebb

Ki vehet részt

  • Clinical \& Angiographic Inclusion Criteria
  • Between 21 and 90 years of age at the time of consent
  • Meets FDA approved indications for transcatheter aortic valve replacement (TAVR) procedure on a native aortic valve using a commercially available Abbott or Medtronic transcatheter heart valve
  • Willing and able to provide written informed consent and written HIPAA authorization prior to initiation of study procedures
  • Willing and able to comply with the protocol-specified procedures and assessments
  • Subject anatomy is compatible with correct device deployment and positioning with:; Ability to achieve access with a 21 French equivalent femoral access sheath; Ascending aorta length ≥8 cm; Ascending aorta/aortic arch diameter is ≥25 or ≤40 mm; Ascending aorta or aortic arch exhibits ≤ Grade 1 atheromatous disease and limited wall calcification

Ki nem vehet részt

  • Previously implanted aortic or mitral valve bioprosthesis
  • Planned to undergo any other cardiac surgical or interventional procedure (e.g., concurrent coronary revascularization) during the TAVR procedure or within 30 days prior to the TAVR procedure. NOTE: Diagnostic cardiac catheterization is permitted up until baseline MRI is obtained. Once baseline MRI is obtained, no additional intra-aortic or intracardiac procedure may occur
  • Documented history of stroke or TIA within the prior 6 months, or any prior stroke with a permanent major disability or deficit (NIHSS >1 at baseline)
  • History of intolerance, allergic reaction, or contraindication to any of the study medications, including heparin, aspirin, clopidogrel, or a sensitivity to contrast media or anesthesia that cannot be adequately pre-treated
  • Currently participating in another drug or device clinical study
  • Hepatic failure (Child-Pugh class C)
  • Acute myocardial infarction within 30 days of the planned index procedure
  • Known allergy or sensitivity to nickel-titanium
  • History of bleeding diathesis or a coagulopathy
  • Renal failure, defined as estimated glomerular filtration rate (eGFR) <30 mL/min
  • Left ventricular ejection fraction ≤30% within 3 months prior to procedure
  • Active endocarditis or ongoing systemic infection, defined as fever (>38°C) and/or white blood cell (WBC) >15,000 IU
  • Known or suspected to be pregnant, or is lactating; female subjects of child-bearing potential must have a negative serum or urine pregnancy test within 48 hours prior to the index study procedure
  • Requires urgent or emergent TAVR procedure
  • Contraindicated to MRI
  • Hypercoagulable state that cannot be corrected by additional periprocedural heparin
  • Undergoing therapeutic thrombolysis
  • Any other clinical reason, as deemed by the investigators of the study, by which the patient would not be an appropriate candidate for the study
  • Vulnerable subject populations (e.g., incarcerated or cognitively challenged adults)

Helyszínek itt: Egyesült Államok

  • Mission HealthAsheville, Egyesült Államok
  • Centennial Medical CenterNashville, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

The objective of this study is to demonstrate device feasibility, safety and investigate performance of the EmStop Embolic Protection System when used as indicated in 15 subjects at 2 investigational sites in the U.S.

A vizsgálat csoportja

  • EmStop Embolic Protection SystemA vizsgált kezelés

    Transcatheter aortic valve replacement (TAVR) procedures with the EmStop Embolic Protection System (EmStop System).

    Kezelés: The EmStop Embolic Protection System (EmStop System)

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
A regiszteradat frissítve
2025. április 29.